Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ampio Pharmaceuticals appoints new CFO

This article was originally published in Scrip

Executive Summary

US-based Ampio Pharmaceuticals has named Mark McGregor chief financial officer and corporate secretary. Bruce Miller, who has served in these roles since April 2010, will join the team that will advance the commercialisation of Ampio's Phase III product candidate, Zertane, which was obtained through the acquisition of DMI BioSciences in 2010. Mr Miller had served as DMI's chief executive officer and/or president since 1992. Ampio is developing proprietary drugs for metabolic, eye and kidney diseases, inflammation, CNS disease and male sexual dysfunction.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts